Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Fletikumab

Generic Name: Fletikumab

Drug Type: Biotech

CAS Number: 1357158-22-5

Unique Ingredient Identifier: 82WG3POL9W

Overview

Fletikumab is under investigation in clinical trial NCT01038674 (Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis).

Background

Fletikumab is under investigation in clinical trial NCT01038674 (Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Phase 2

Withdrawn

Posted: 2014/03/27

Sponsor:Novo Nordisk A/S

ID:NCT02097264

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Phase 2

Terminated

Posted: 2012/07/10

Sponsor:Novo Nordisk A/S

ID:NCT01636817

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Phase 2

Terminated

Posted: 2012/07/10

Sponsor:Novo Nordisk A/S

ID:NCT01636843

First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects

Phase 1

Terminated

Posted: 2010/12/16

Sponsor:Novo Nordisk A/S

ID:NCT01261767

Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis

Phase 1

Completed

Posted: 2009/12/24

Sponsor:Novo Nordisk A/S

ID:NCT01038674

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy